A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil

International Journal of Clinical Practice

Volumn 60, Issue 10, 2006, Pages 1172-1177

  Pompeo, Antonio Carlos Lima ^a,j   Rosenblatt, C ^b   Bertero, E ^c   Da Ros, C T ^d   Cairoli, C E D ^e   Damiao R ^f   Wroclawski, E R ^g   Koff, W J ^h   Mesquita, F ⁱ   Pinheiro, G E ⁱ  

^a IMEG   (Brazil)

^b Hospital Sao Luiz   (Brazil)

^c HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^d Santa Casa de Porto Alegre   (Brazil)

^e PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^g FACULDADE DE MEDICINA DO ABC   (Brazil)

^h HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

ⁱ HOSPITAL GERAL DE FORTALEZA   (Brazil)

^j NONE   (Brazil)

more..

Author keywords

Benign prostatic hyperplasia; Doxazosin; Ejaculation; Gastrointestinal therapeutic system; International prostate symptom score; Prostate; Tamsulosin

Indexed keywords

DOXAZOSIN; TAMSULOSIN;

ADULT; AGED; ARTICLE; ASTHENIA; BRAZIL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EJACULATION DISORDER; FLU LIKE SYNDROME; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRECORDIAL PAIN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; SCORING SYSTEM; SEXUAL FUNCTION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33748520861     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01107.x     Document Type: Article

References (20)

1. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
2. Berry SJ, Coffey DS, Walsh PC et.al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
3. Debruyne FM. Alpha blockers: Are all created equal ? Urology 2000; 56: 20-2.
4. Chapple C. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience. Eur Urol 1996; 29: 129-44.
5. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-66.
6. Fawzy A, Braun K, Lewis GP et.al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 1995; 154: 105-9.
7. De Reijke TM, Klarskov P. Comparative efficacy and tolerability of two a1-Adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms due to benign prostatic enlargement. BJU Int 2004; 93: 757-62.
8. Chung M, Vashi V, Puente J et.al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87.
9. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-9.
10. Kirby RS, Quinn S, Mallen S et.al. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: An efficacy analysis. Int J Clin Pract 2004; 58: 6-10.
11. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 41-4.
12. 1c-adrenoceptor antagonist: A randomized controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). Br J Urol 1995; 76: 325-36.
13. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-6.
14. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-70.
15. Kirby RS, Andersen M, Gratzke P et.al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
16. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-35.
17. Jimenez-Garcia R, Anegon M, Esteban J et.al. Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients. Int J Clin Pract 2003; 57: 267-72.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: A review of hypertension and BPH studies. Blood Press 2003; 12: 5-13.
19. McConnell JD, Roehrborn CG, Bautista OM et.al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
20. Pfizer A. Cardura XL (Doxazosin Mesylate Extended Release Tablets). New York, NY, USA: Pfizer Inc, 2006.